Financial Comparison: CoLucid Pharmaceuticals (CLCD) vs. Evoke Pharma (EVOK)

CoLucid Pharmaceuticals (NASDAQ: CLCD) and Evoke Pharma (NASDAQ:EVOK) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.

Institutional and Insider Ownership

64.2% of CoLucid Pharmaceuticals shares are held by institutional investors. Comparatively, 12.9% of Evoke Pharma shares are held by institutional investors. 13.7% of CoLucid Pharmaceuticals shares are held by insiders. Comparatively, 20.0% of Evoke Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

CoLucid Pharmaceuticals has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500. Comparatively, Evoke Pharma has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500.

Earnings and Valuation

This table compares CoLucid Pharmaceuticals and Evoke Pharma’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
CoLucid Pharmaceuticals N/A N/A N/A ($3.44) -13.53
Evoke Pharma N/A N/A N/A ($0.97) -3.14

CoLucid Pharmaceuticals is trading at a lower price-to-earnings ratio than Evoke Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares CoLucid Pharmaceuticals and Evoke Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CoLucid Pharmaceuticals N/A -83.51% -70.62%
Evoke Pharma N/A -167.16% -80.56%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for CoLucid Pharmaceuticals and Evoke Pharma, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CoLucid Pharmaceuticals 0 3 1 0 2.25
Evoke Pharma 0 1 6 0 2.86

CoLucid Pharmaceuticals presently has a consensus target price of $47.83, indicating a potential upside of 2.80%. Evoke Pharma has a consensus target price of $8.86, indicating a potential upside of 190.40%. Given Evoke Pharma’s stronger consensus rating and higher probable upside, analysts plainly believe Evoke Pharma is more favorable than CoLucid Pharmaceuticals.

Summary

Evoke Pharma beats CoLucid Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About CoLucid Pharmaceuticals

CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company’s lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.

About Evoke Pharma

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.

What are top analysts saying about CoLucid Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CoLucid Pharmaceuticals Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit